No Data
There's No Escaping Metagenomi, Inc.'s (NASDAQ:MGX) Muted Revenues Despite A 89% Share Price Rise
Wells Fargo Maintains Metagenomi Technologies, LLC(MGX.US) With Buy Rating, Maintains Target Price $25
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference "RNA at the Bench and Bedside IV"
Expert Outlook: Metagenomi Through The Eyes Of 4 Analysts
Express News | Metagenomi Shares Halted On Circuit Breaker To The Upside, Stock Now Up 11.8%
Metagenomi Is Maintained at Buy by HC Wainwright & Co.
